AU2019386235B2 - Montelukast for the treatment of erosive hand osteoarthritis - Google Patents

Montelukast for the treatment of erosive hand osteoarthritis Download PDF

Info

Publication number
AU2019386235B2
AU2019386235B2 AU2019386235A AU2019386235A AU2019386235B2 AU 2019386235 B2 AU2019386235 B2 AU 2019386235B2 AU 2019386235 A AU2019386235 A AU 2019386235A AU 2019386235 A AU2019386235 A AU 2019386235A AU 2019386235 B2 AU2019386235 B2 AU 2019386235B2
Authority
AU
Australia
Prior art keywords
montelukast
pharmaceutically acceptable
day
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019386235A
Other languages
English (en)
Other versions
AU2019386235A1 (en
Inventor
Fernando García Alonso
Jordi MONFORT FAURE
Jordi RAMENTOL MASSANA
Nuria SANZ MENÉNDEZ
José Ángel SÁNCHEZ GARCÍA
Josep Verges Milano
Marta Vicario De La Torre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmalider SA
Original Assignee
Farmalider SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider SA filed Critical Farmalider SA
Publication of AU2019386235A1 publication Critical patent/AU2019386235A1/en
Assigned to FARMALIDER, S.A. reassignment FARMALIDER, S.A. Request for Assignment Assignors: MMC INTELLECTUAL PROPERTY INSTITUTE, S.L.
Application granted granted Critical
Publication of AU2019386235B2 publication Critical patent/AU2019386235B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019386235A 2018-11-26 2019-11-25 Montelukast for the treatment of erosive hand osteoarthritis Active AU2019386235B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382851 2018-11-26
EP18382851.6 2018-11-26
PCT/EP2019/082425 WO2020109230A1 (en) 2018-11-26 2019-11-25 Montelukast for the treatment of erosive hand osteoarthritis

Publications (2)

Publication Number Publication Date
AU2019386235A1 AU2019386235A1 (en) 2021-07-01
AU2019386235B2 true AU2019386235B2 (en) 2024-11-21

Family

ID=64665075

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019386235A Active AU2019386235B2 (en) 2018-11-26 2019-11-25 Montelukast for the treatment of erosive hand osteoarthritis

Country Status (22)

Country Link
US (1) US12539296B2 (enExample)
EP (1) EP3886857B1 (enExample)
JP (1) JP7399502B2 (enExample)
CN (1) CN113347975B (enExample)
AU (1) AU2019386235B2 (enExample)
BR (1) BR112021009980A2 (enExample)
CA (1) CA3120920C (enExample)
DK (1) DK3886857T3 (enExample)
ES (1) ES2961390T3 (enExample)
FI (1) FI3886857T3 (enExample)
HR (1) HRP20231283T1 (enExample)
HU (1) HUE063579T2 (enExample)
MA (1) MA54276B1 (enExample)
MD (1) MD3886857T2 (enExample)
MX (1) MX2021006209A (enExample)
MY (1) MY203365A (enExample)
PL (1) PL3886857T3 (enExample)
PT (1) PT3886857T (enExample)
RS (1) RS64668B1 (enExample)
SI (1) SI3886857T1 (enExample)
TW (1) TWI850283B (enExample)
WO (1) WO2020109230A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4228641A1 (en) * 2020-10-13 2023-08-23 Diomed Developments Limited Gel formulations comprising montelukast
GB2599912B (en) * 2020-10-13 2023-04-19 Diomed Dev Ltd New formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201020085D0 (en) * 2010-11-26 2011-01-12 Xaragen Pharma Ltd Methods and reagents for the treatment of arthritic disorders
CA2931978A1 (en) 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FANNING P J ET AL: "527 MONTELUKAST SODIUM AS A TREATMENT FOR EXPERIMENTAL OSTEOARTHRITIS IN MICE", OSTEOARTHRITIS AND CARTILAGE, vol. 17, 1 September 2009 (2009-09-01), pages S282 - S283, DOI: 10.1016/S1063-4584(09)60548-3 *
WEI SONG ET AL: "Antagonism of cysteinyl leukotriene receptor 1 (cysLTR1) by montelukast suppresses cell senescence of chondrocytes", CYTOKINE, vol. 103, 1 March 2018 (2018-03-01), US, pages 83 - 89, DOI: 10.1016/j.cyto.2017.12.021 *

Also Published As

Publication number Publication date
MX2021006209A (es) 2021-08-11
SI3886857T1 (sl) 2023-12-29
PT3886857T (pt) 2023-10-25
HUE063579T2 (hu) 2024-01-28
RS64668B1 (sr) 2023-11-30
JP2022508236A (ja) 2022-01-19
TWI850283B (zh) 2024-08-01
US20220047570A1 (en) 2022-02-17
FI3886857T3 (fi) 2023-10-20
EP3886857A1 (en) 2021-10-06
CA3120920A1 (en) 2020-06-04
JP7399502B2 (ja) 2023-12-18
MD3886857T2 (ro) 2023-12-31
PL3886857T3 (pl) 2024-01-15
CN113347975B (zh) 2024-08-30
AU2019386235A1 (en) 2021-07-01
CA3120920C (en) 2024-01-02
DK3886857T3 (da) 2023-10-09
ES2961390T3 (es) 2024-03-11
WO2020109230A1 (en) 2020-06-04
US12539296B2 (en) 2026-02-03
EP3886857B1 (en) 2023-07-26
BR112021009980A2 (pt) 2021-08-17
HRP20231283T1 (hr) 2024-02-02
MY203365A (en) 2024-06-26
MA54276B1 (fr) 2023-11-30
TW202038954A (zh) 2020-11-01
CN113347975A (zh) 2021-09-03
MA54276A (fr) 2021-10-06

Similar Documents

Publication Publication Date Title
US20220152054A1 (en) Methods and compositions for treating various disorders
CN104470516A (zh) 鼻内右美托咪定组合物和其使用方法
ES2741146T3 (es) Formulaciones farmacéuticas de nitrio y sus usos
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
KR20150139830A (ko) 신경변성 및 기타 질환의 치료를 위한 조성물 및 방법
EP2568806A1 (en) Therapeutic regimens
AU2019386235B2 (en) Montelukast for the treatment of erosive hand osteoarthritis
US12295933B2 (en) Methods and compositions to treat and diagnose diseases or pathologies associated with inflammation of the sinuses and nasal cavity
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
JP7745571B2 (ja) 肺線維症を処置する方法
RU2809024C2 (ru) Монтелукаст для лечения эрозивного остеоартрита кистей рук
RU2101014C1 (ru) Анальгезирующее, противовоспалительное, жаропонижающее лекарственное средство и способ его получения
HK40054679A (en) Montelukast for the treatment of erosive hand osteoarthritis
HK40054679B (en) Montelukast for the treatment of erosive hand osteoarthritis
WO2024129782A1 (en) Regimens and compositions useful for alleviating pain
JP6042886B2 (ja) 早漏症治療用の薬学組成物
KR20230018481A (ko) 질병의 치료를 위한 2-(다이에틸아미노)에틸 2-(4-아이소부틸페닐)프로피오네이트의 국소 투여
EP0868915A1 (en) An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
US20220304959A1 (en) Treatment of long haulers syndrome with niclosamide
EP4633628A1 (en) Regimens and compositions useful for alleviating pain
KR20060123329A (ko) 월경 곤란증의 예방 및/또는 치료제
Mounnissamy International Journal Research Publication Analysis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: FARMALIDER, S.A.

Free format text: FORMER APPLICANT(S): MMC INTELLECTUAL PROPERTY INSTITUTE, S.L.

FGA Letters patent sealed or granted (standard patent)